Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores

Tyler W. Buckner, Nabil Daoud, Lucy Lee, Elise Lim, Jonathan Schwartz, Karina Raimundo, Michael Recht

Blood (2023) 142 (Supplement 1): 3998.

https://doi.org/10.1182/blood-2023-174092

Published: 2023

Journal Articles

Emicizumab and Females with Hemophilia A: Case Series from ATHN 7

Michael Recht, Nabil Daoud, Lucy Lee, Paul Morton, Leslie J. Raffini

Blood (2022) 140 (Supplement 1): 2745–2746.

https://doi.org/10.1182/blood-2022-157754

Published: 2022

Journal Articles

Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis

Arash Mahajerin, Rahul Khairnar, Craig S. Meyer, Ibrahim M. Abbass, Rongrong Wang, Lucy Lee, Eunice Tzeng, Karina Raimundo

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-137632

Published: 2020

Journal Articles

A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures

Miguel A. Escobar, MD, Amy Dunn, Doris Quon, MD PhD, Ben Trzaskoma, Lucy Lee, Richard H Ko, Shannon L Carpenter, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134906

Published: 2020

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath

Blood (2019) 134 (Supplement_1): 2395.

https://doi.org/10.1182/blood-2019-123654

Published: 2019

NARROW

Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores

Emicizumab and Females with Hemophilia A: Case Series from ATHN 7

Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis

A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Email alerts

ASH Publications

American Society of Hematology

Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores

Emicizumab and Females with Hemophilia A: Case Series from ATHN 7

Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis

A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only